Study of Lipoprotein(a) Levels in Patients With a History of ASCVD
Research type
Research Study
Full title
A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a)Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)
IRAS ID
310751
Contact name
Azfar Zaman
Contact email
Sponsor organisation
Amgen
Clinicaltrials.gov Identifier
www.amgentrials.com/s/20210057, Summary of Results Website
Duration of Study in the UK
0 years, 9 months, 3 days
Research summary
Lipoprotein(a) or Lp(a), for short, is a protein which transports cholesterol, a fatty substance, in the blood. There are two main types of lipoprotein: high-density lipoprotein (HDL) cholesterol, which is often referred to as good cholesterol, and low-density lipoprotein (LDL), or bad, cholesterol.
Lp(a) is an LDL created in the liver, and the amount an individual produces is mostly determined by their genetics. High levels of Lp(a) in the blood, have been previously linked to an increased risk in Atherosclerotic Cardiovascular Disease (ASCVD) and ASCVD events, such as heart attacks or aortic stenosis (a narrowing of the aortic valve opening). For patients who have known ASCVD, many do not undergo routine blood testing of their Lp(a) levels. Until more recently, the role of Lp(a) was not well understood and therefore, it was not routinely tested for in clinical practice. Therefore the known levels of Lp(a) levels within patients who have known ASCVD, especially within each country/region, is limited.
The aim of this research is to collect data on Lp(a) in patients with known ASCVD, who have a documented history of Myocardial Infarction (heart attacks) or have undergone a Percutaneous Coronary Intervention (a non-surgical procedure used to treat narrowing of the coronary arteries of the heart). This will help the Sponsor to better understand the risk of elevated Lp(a) in patients with ASCVD.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
22/EM/0102
Date of REC Opinion
10 May 2022
REC opinion
Further Information Favourable Opinion